Table 13Overview: other adverse events

Adverse EventVariableEpoetin vs. ControlDarbepoetin vs. ControlEpoetin or Darbepoetin vs. Control
HypertensionNumber of trials13a316
Patients analyzed3,0211,2974,318
Pooled relative risk1.621.311.48
(95% confidence interval)(1.05 to 2.50)(0.79 to 2.18)(1.07 to 2.06)
I20%0%0%
Thrombocytopenia/HemorrhageNumber of trials10212
Patients analyzed2,4031,3113,714
Pooled relative risk1.111.461.17
(95% confidence interval)(0.94 to 1.31)(1.03 to 2.06)(1.01 to 1.36)
I20%0%0%
RashNumber of trials55
Patients analyzed1,4671,467
Pooled relative risk2.002.00
(95% confidence interval)(0.98 to 4.07)(0.98 to 4.07)
I20%0%
SeizuresNumber of trials325
Patients analyzed6049831,587
Pooled relative risk1.490.880.93
(95% confidence interval)(0.45 to 4.87)(0.14 to 5.41)(0.43 to 2.04)
I20%54%0%
a

Two other trials not included in pooled result—one with no events in either arm and one outlier (15 trials reported hypertension outcomes).

Two other trials not included in pooled result—one with no events in either arm and one outlier (15 trials reported hypertension outcomes).

From: Results

Cover of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment
Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update [Internet].
Comparative Effectiveness Reviews, No. 113.
Grant MD, Piper M, Bohlius J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.